Specifically, the downregulation of IGF2BP1 in melanoma cells was shown to bolster the growth‐inhibitory influence of IFN signals and enhance the susceptibility of tumors to anti‐PD1 treatment in both murine and human melanoma models. The gene discussed is IGF2BP1; the disease is melanoma.